DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

PODD·Insulet Corporation

$.
-. (-.%)
After Hours
High
$149.10
Open
$143.91
Market Cap
10.74B
52W High
$354.88
Low
$141.02
P. Close
$146.02
P/E
35.45
52W Low
$145.59
Fwd P/E
19.08
Mean Target
$245.75
Technical Score (1D)
23
SELL
News Sentiment
61
BULLISH
Goldman Sachs has adjusted its price target for Insulet (PODD) downwards to $205 from $237, while maintaining a 'Buy' rating, indicating a recalibration of short-term valuation expectations but continued confidence in long-term prospects. This analyst action follows Insulet's recent initiation of a voluntary medical device correction for specific lots of its Omnipod devices due to a manufacturing issue that could lead to insulin under-delivery. The correction impacts Omnipod 5, Omnipod DASH, and Omnipod Eros systems in both U.S. and international markets, with the company distinguishing these affected lots from prior corrections. This voluntary action addresses potential product performance concerns stemming from a small tear in the cannula tubing. Insulet's inclusion in after-market healthcare stock movers suggests ongoing investor attention to the company. Traders should monitor any further details regarding the scope and resolution of the manufacturing issue, as well as any subsequent analyst commentary or company updates that could influence near-term sentiment.
Earnings Summary
Insulet Corporation is a medical device company focused on developing and manufacturing innovative insulin delivery systems for individuals with insulin-dependent diabetes, primarily through its Omnipod platform. Operating within the Healthcare sector's Medical Devices industry, the company's core products include the automated Omnipod 5 system and the Omnipod DASH system, alongside manufacturing pods for Amgen's Neulasta Onpro kit. In the most recent reported quarters, Insulet demonstrated a mixed performance against analyst expectations. For Q4 2025, the company reported EPS of $1.55, exceeding the estimate of $1.17827, and revenue of $783.8 million, surpassing the estimate of $714.3266 million. However, in Q1 2026, while EPS of $1.42 beat the estimate of $1.1907, revenue of $761.7 million fell short of the $730.10084 million estimate. This pattern suggests a recent trend of EPS beats alongside occasional revenue misses. Historically, Insulet has shown a trajectory of growth, with notable beats in EPS in Q4 2025 and Q1 2026, although revenue performance has been less consistent, missing estimates in Q1 2026. Recent news highlights analyst optimism regarding Insulet's long-term growth, with Benchmark initiating coverage with a "Buy" rating and a $250 price target, citing strategic international expansion in the Middle East and North Africa. Despite strong Q1 revenue growth driven by Omnipod 5 adoption, concerns about the growth trajectory have led some analysts, like Goldman Sachs, to reduce price targets. Investors will be watching for continued adoption of the Omnipod 5, particularly in the type 2 diabetes segment, and how the company navigates seasonality and insurance deductible resets in its upcoming quarterly reports, as well as the impact of its international expansion efforts on overall growth and profitability.

EPS

EstBeatMiss
$0.67$0.92$1.17$1.42$1.66Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.45 - -
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%
Q1'25$0.79$1.02+29.7%

Revenue

EstBeatMiss
$534M$610M$685M$760M$836MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$801M - -
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -
Q1'25 - $569M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PODD Stock Snapshot

PODD is currently trading at $147.59, giving Insulet Corporation a market cap of 10.74B and a P/E ratio of 35.5. Today's range spans $141.02–$149.10, with shares opening at $143.91 and moving up $1.57 (1.1%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 61/100.

Over the past year PODD has traded between $145.59 and $354.88 - the current price is +1.4% off the 52-week low and -58.4% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $245.75 (range $175.00–$360.00), implying upside of +66.5%.

PODD scores 23/100 (SELL) and trades at $147.59 - near 52-week lows in the $145.59–$354.88 annual range. Sentiment at 61/100 is bullish. (P/E: 35.5) For a large-cap in Healthcare with 10.74B in capitalization, a SELL signal means that sector rotation money leaving Healthcare will likely exit through names like this first - the combination of negative technicals and bullish news flow is exactly what systematic sector rotation models identify as underweight candidates.

The current SELL phase for PODD (23/100) at $147.59 (near 52-week lows) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 61/100 (bullish) confirms that news flow is not providing a counternarrative. At 10.74B in Healthcare capitalization, PODD has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $145.59–$354.88 range.